Mark Lupher Jr. - Jun 17, 2024 Form 4 Insider Report for Adverum Biotechnologies, Inc. (ADVM)

Role
Director
Signature
/s/ John Rakow, Attorney-in-Fact
Stock symbol
ADVM
Transactions as of
Jun 17, 2024
Transactions value $
$0
Form type
4
Date filed
6/20/2024, 04:48 PM
Previous filing
Feb 9, 2024

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ADVM Stock Option (Right to Buy) Award $0 +10.5K $0.00 10.5K Jun 17, 2024 Common Stock 10.5K $7.32 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The shares subject to the option will vest and become exercisable on the earlier of June 17, 2025 or the 2025 annual meeting of stockholders, subject to (1) accelerated vesting upon a change of control and (2) the Reporting Person's continued service with the Issuer on the vesting date.